Hoth Therapeutics Shares Advance Following Promising CLEER-001 Trial Interim Data
Hoth Therapeutics Inc's stock increased notably on positive interim findings from the open-label pharmacokinetic segment of its CLEER-001 trial assessing HT-001 in cancer patients undergoing EGFR inhibitor therapy. The results demonstrated full clinical response by Week 6 among evaluable participants, significant reductions in disease severity and …